GAITHERSBURG, Md. – After two days of often very contentious debate over the validity and reliability of data from numerous studies of GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone), an FDA panel said in a split vote that the drug should remain on the U.S. market, but with new warnings about heart attacks and under limited use. (BioWorld Today)